Physician

Peter J Kourlas, MD

According to 2025 Medicare claims, Peter Kourlas, MD (NPI: 1700882818) practices hematology/oncology in the Columbus, OH market, with the plurality of this provider's patient population coming from Franklin, OH. This provider's primary affiliated billing organization is COLUMBUS ONCOLOGY ASSOCIATES INC (NPI: 1790875656; TIN: 311211874) and primary practice location at 43214-4359.

Kourlas' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 451 traditional Medicare patients, billed 141,961 HCPCS/CPT codes, and received $3,321,926 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 1,691 prescription claims across 207 beneficiaries totaling $5,947,578 in drug costs, led by Revlimid (Lenalidomide). DME data shows 38 claims. Open Payments data shows 2 records. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $698,772 to $3,321,926. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,030,241 to $5,947,578. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	284	69,971	$698,772
2016	381	105,833	$1,369,864
2017	385	99,018	$1,269,201
2018	413	91,037	$1,149,466
2019	397	73,684	$1,324,861
2020	338	74,859	$1,199,696
2021	404	102,368	$1,207,321
2022	443	83,307	$997,892
2023	438	94,023	$1,695,240
2024	451	141,961	$3,321,926

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	155	1,043	$1,030,241
2016	179	1,188	$1,668,880
2017	179	1,334	$2,109,064
2018	190	1,481	$3,053,894
2019	180	1,624	$3,603,482
2020	164	1,320	$3,469,017
2021	178	1,430	$5,592,279
2022	187	1,590	$5,274,338
2023	188	1,514	$3,950,219
2024	207	1,691	$5,947,578

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	71	$2,138
2016	N/R	115	$32,925
2017	N/R	118	$19,429
2018	N/R	31	$6,568
2019	N/R	34	$4,713
2020	N/R	51	$4,446
2021	N/R	74	$5,266
2022	N/R	32	$1,199
2023	N/R	70	$6,959
2024	N/R	38	$873

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	87	218	$127
96413	Administration of chemotherapy into vein, 1 hour or less	67	297	$92
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	246	756	$89
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	106	130	$58
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	276	662	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	45	1,260	$964,897
Calquence	Acalabrutinib Maleate	46	1,380	$694,389
Lenalidomide	Lenalidomide	44	1,232	$693,206
Ibrance	Palbociclib	37	1,058	$583,995
Cabometyx	Cabozantinib S-Malate	19	570	$511,054

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8700	Temozolomide, oral, 5 mg	N	N/R	13	$491
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	11	$207
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	14	$176

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	0	$0	N/R
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	2	$9,000	Cornerstone Specialty Network LLC

Explore More Providers

FAQ

What Medicare data is available for Peter J. Kourlas, MD?

Tedicare shows public-source Medicare data for Peter J. Kourlas, MD (NPI 1700882818), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Peter J. Kourlas, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Peter J. Kourlas, MD?

Peter J. Kourlas, MD is linked to COLUMBUS ONCOLOGY ASSOCIATES INC (billing NPI 1790875656) in the available physician profile data.

Does Peter J. Kourlas, MD have Open Payments data?

Peter J. Kourlas, MD has 2 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.